MALKIAH ENGELSBERG: Open Payments
NPI 1336649755 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$330 in 12 payments from 8 companies in 2025. Trend: 2023 $618 · 2024 $310 · 2025 $330
Food & beverage: $330
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 1 | $113 |
| Alexion Pharmaceuticals, Inc. | 2 | $66 |
| Merck Sharp & Dohme LLC | 2 | $31 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $31 |
| Gilead Sciences, Inc. | 2 | $29 |
| ABBVIE INC. | 1 | $23 |
| PFIZER INC. | 1 | $21 |
| E.R. Squibb & Sons, L.L.C. | 1 | $17 |
Products named: FABRAZYME, ULTOMIRIS, ELIQUIS, ZERBAXA, XIFAXAN, Veklury, UBRELVY.
Industry payments across MD — which companies pay providers there.
